Britain and America have agreed to a significant commercial pact that will ensure no duties on UK pharmaceutical shipments entering the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on medicines through the National Health Service (NHS). This commitment guarantees that tariffs on these crucial products will stay at nothing for a period of 36 months.
This deal follows recent statements to dramatically increase import taxes on branded pharmaceutical imports, with figures floated as high as double the cost.
"This agreement between the UK strengthens the international landscape for innovative medicines and introduces long-overdue equity to transatlantic pharmaceutical trade," an announcement said.
Economic Impact
Medicines are one of the the United Kingdom's largest export categories to the America, which is by far the largest market for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period prior to the third quarter, the UK sold drugs valued at billions to the US. This value made up 17.4% of British export trade in that span.
"This guarantee safeguards employment, increases capital expenditure and paves the way for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The agreement entails several key pledges from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to double total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be capped at 15%. Previously, refunds topped twenty percent.
Broader Context
The deal comes amid a ongoing tension between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were heightened by arguments that US patients were paying significantly more for the same drugs than people in the UK and Europe.
Recently, several major manufacturing plans in the UK have been paused or abandoned, while substantial investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.
